Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mark Gromski

Gastroenterology Indianapolis, IN Medical Doctor

NPI 1255625679 CMS profile 883161

1701 N Senate Blvd, Indianapolis, IN 46202

Open in the dashboard

General payments

$154,240

189 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$253,500 paid to institutions, not to them · program years 2023–2025

Through program year 2025, Mark Gromski of Indianapolis, IN is reported in the CMS Open Payments database as having received $154,240 across 189 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $253,500 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $41,702 51
2024 General $39,560 43
2023 General $24,693 26
2022 General $24,988 33
2021 General $15,930 21
2020 General $5,022 6
2019 General $2,344 9

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mark Gromski
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Mark Gromski were reported at $41,702. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Mark Gromski Gastroenterology median Middle half National median
2019 $2,344 $417 $126–$1,100 $163
2020 $5,022 $224 $74–$624 $114
2021 $15,930 $352 $106–$1,054 $132
2022 $24,988 $448 $129–$1,270 $149
2023 $24,693 $533 $150–$1,390 $160
2024 $39,560 $605 $160–$1,606 $164
2025 $41,702 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $109,463 150 payments
  2. Wilson Cook Medical Incorporated $26,084 12 payments
  3. Ambu A/S $12,403 1 payment
  4. Cook Research Incorporated $3,000 1 payment
  5. Cook Medical LLC $1,824 12 payments
  6. Ambu Inc. $767 4 payments
  7. Omega Medical Imaging, LLC $173 2 payments
  8. Olympus America Inc. $149 1 payment
  9. Salix Pharmaceuticals, a division of Bausch Health US, LLC $131 3 payments
  10. CONMED Corporation $131 1 payment
  11. Other $116 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $101,468 58 payments
  2. Consulting Fee $40,256 16 payments
  3. Travel and Lodging $7,112 30 payments
  4. Food and Beverage $5,405 85 payments
Products named General payments · program years 2019–2025
  1. EXALT Model D Exalt_Endo $16,591 22 payments
  2. General - Therapies $15,734 13 payments
  3. FUSION $14,679 14 payments
  4. EXALT Model D EXALT Model D_ENDO $12,842 27 payments
  5. EXALT Model D EXALT Model D_ENDO $12,272 6 payments
  6. SpyGlass $4,925 4 payments
  7. EXALT $4,150 6 payments
  8. EXALT BX 2 $3,950 3 payments
  9. EXALT MODEL D CONTROLLER $3,938 2 payments
  10. GENERAL BILIARY DEVICES $3,800 2 payments
  11. Other $13,101 61 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

119

Median for Gastroenterology: 569

Drug cost

$71,859

Median for Gastroenterology: $104,976

Branded share of claims

28.6%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Creon Lipase/Protease/Amylase Brand 12 $70,469
Dicyclomine Hcl Generic 19 $544
Omeprazole Generic 23 $424
Pantoprazole Sodium Generic 29 $338
Ciprofloxacin Hcl Generic 14 $42
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 22 $41

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 53 billing codes

Paid by Medicare

$49,559

Medicare's payments for the services billed

Medicare patients

203

Average age 71

Services billed

497

116 women, 87 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 51%
Diabetes 44%
Depression 34%
Ischemic heart disease 31%
Chronic kidney disease 28%
COPD 21%
Atrial fibrillation 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

189 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record